Screening for cerebroprotective agents using an in vivo model of cerebral reversible depolarization in awake rats

Pharmacological Research

Volumn 44, Issue 5, 2001, Pages 419-429

  Bodo, Michael ^a   Perjes, Gabriella ^b   Kalman, Eszter ^b   Bacskai, Emma ^b   Berko, Klara ^b   Sarkadi, Adam ^b   Nagy, Istvan ^b   Keim, Kevin L ^c   Matysik, Frank M ^d   Csomor, Katalin ^b   McCarron, Richard ^e   Zagvazdin, Yuri ^f   Rosenthal, Myron ^g   Morrissette, Craig ^a   Herendy, Edit ^b   Szporny, Laszlo ^b   Nagy, Zoltan ^h  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b GEDEON RICHTER LTD   (Hungary)

^c Vela Pharmaceuticals   (United States)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e NAVAL MEDICAL RESEARCH CENTER   (United States)

^f NOVA SOUTHEASTERN UNIVERSITY   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h National Stroke Centre   (Hungary)

Author keywords

Awake rat; Hypoxia; Isoelectric EEG; Pharmaceutical screening; Reversible depolarization

Indexed keywords

NEUROPROTECTIVE AGENT; NITROGEN; POSATIRELIN;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; BRAIN OXYGEN TENSION; BRAIN PROTECTION; CARBON DIOXIDE TENSION; CONTROLLED STUDY; DEPOLARIZATION; DOSE RESPONSE; DRUG SCREENING; ELECTROENCEPHALOGRAM; HYPOXIA; IN VIVO STUDY; MALE; NONHUMAN; PH; PRIORITY JOURNAL; RAT; SCORING SYSTEM; VIBRISSA; WAKEFULNESS; WITHDRAWAL REFLEX;

EID: 0035193085     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2001.0882     Document Type: Article

References (83)

1. Clinical trials with neuroprotective drugs in acute ischemic stroke: Are we doing the right thing?
2. Local effect of anesthesia on cerebral blood flow in the rat
3. Effects of halothane and urethane-chloralose anaesthesia on the pressor and cerebrovascular responses to 7-nitroindazole, an inhibitor of nitric oxide synthase
4. Cerebroprotective drugs shorten the hypoxia-induced onset of electrical silence in unanesthetized rats
5. New reversible brain death model on rat: Electroanalytical results
6. Lipid peroxidative background of slow hypoxia in rat brain
7. + at critical levels of brain ischemia
8. Drugs against brain hypoxia
9. Cerebral resuscitation: Pathophysiology and therapy
10. Brain damage in a new hemorrhagic shock model in the rat using long-term recovery
11. EEG suppression and anoxic depolarization: Influences on cerebral oxygenation during ischemia
12. Application of hypoxic model in estimation of cerebral blood flow by electrochemically generated hydrogen
13. Principles of toxicology
14. A model of gradual onset brain death for transplant-associated studies in rats
15. Guideline three: Minimum technical standards for EEG recording in suspected cerebral death
16. Medical technology assessment: EEG and evoked potentials in the intensive care unit
17. European brain death codes: A comparison of national guidelines
18. Progressive hypoxia until brain electrical silence: A useful model for studying protective interventions
19. Cerebral anoxia
20. Pathophysiology of the ischemic penumbra - Revision of a concept
21. Rheoencephalographic changes during increased intracranial pressure
22. Drug screening and evaluation of new compounds in animals
23. General anesthetics
24. Reactive oxygen species and neuronal function
25. The hypoxic brain: Insights from ischemic research
26. Cerebral autoregulation
27. The metabolic function of oxygen and biochemical lesions of hypoxia
28. Distributing working versions of published mathematical models for biological systems via the internet
29. Evaluation of critical oxygen supply in the brain cortex
30. Model of blood-brain transfer of oxygen explains nonlinear flow-metabolism coupling during stimulation of visual cortex
31. Mechanisms of secondary brain injury
32. Influence of preischemic hyperglycemia on osmolality and early postischemic edema in the rat brain
33. Stroke: The first hours. Emergency evaluation andtreatment
34. Neuroprotection as initial therapy in acute stroke. Third report of an ad hoc consensus group meeting
35. Inflammatory mediators and stroke: New opportunities for novel therapeutics
36. The management of drug discovery
37. Cognition enhancers, agents, and pharmacodynamic models for Alzheimer's disease
38. Simultaneous quantitative evaluation of visual-evoked responses and background EEG activity in rat: Normative data
39. Central nervous system effects of ginkgo biloba, a plant extract
40. Hypoxia-induced sleep disturbance in rats
41. Classification of drugs based on visually evoked responses in rats
42. Standard operating procedure (SOP) for the registration and computer-supported evaluation of pharmaco-EEG data. Working Team 'EEG in Phase I' of CIPS
43. Brain vulnerability and survival during anoxia: Protective strategies of hypokia-resistant vertebrates
44. Maintaining coupled metabolism and membrane function in anoxic brain: A comparison between the turtle and rat
45. 2 during acute hypoxia in rat brain using a time-resolved luminescence-based oxygen sensor
46. Stages of cerebral hypoxia
47. 2 and cerebral blood flow in hypokic hypoxia
48. Reperfusion damage following focal ischemia: Pathophysiology and therapeutic windows
49. Oxygen radicals and the nervous system
50. Protection against hypoxic/ischemic brain damage with excitatory amino acid antagonists
51. Modulation of pH by neuronal activity
52. EEG-EMG zeitschrift fur elektroenzephalographie
53. Projecting future drug expenditures - 2000
54. The effect of pharmacoeconomics on company research and development decisions
55. Responsibilities of clinical pharmacology in the early phase of drug development
56. Drug discovery and development in the pharmaceutical industry
57. Editor's note
58. General pharmacological studies in the pharmaceuticalindustry: Example of a basic program
59. Neuroprotection in acute ischemic stroke. Current status and future potential
60. TRH analog administration increases endogenous TRH levels in the central nervous system
61. Effects of thyrotropin-releasing hormone and its analogue L-6-ketopiperidine-2-carbonyMeucyl-L-prolin-amide on behaviour and electroencephalogram
62. Protective effects of TRH and its stable analogue, RGH-2202, on kainatednduced seizures and neurotoxicity in rodents
63. Clinical potential for the use of neuroprotective agents
64. Neuroprotection in surgery: Development of a pharmacologic cocktail for intraoperative use
65. To what extent have functional studies of ischemia in animals been useful in the asses sment of potential neuroprotective agents?
66. Multiple molecular penumbras after focal cerebral ischemia
67. Current and future approaches to neurotoxicity risk assessment
68. Clinical trials in acute stroke: Why have they not been successful?
69. Why do neuroprotective drugs work in animals but not in humans?